Silence Therapeutics plc
SLNCF
$1.80
$0.2012.50%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.71% | 24.64% | -14.37% | 41.49% | -41.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.71% | 24.64% | -14.37% | 41.49% | -41.92% |
| Cost of Revenue | -77.99% | -37.10% | -5.37% | -3.89% | -28.21% |
| Gross Profit | 170.18% | 72.53% | -18.24% | 72.68% | -53.35% |
| SG&A Expenses | -4.26% | 8.75% | 19.11% | 9.47% | 7.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.99% | 35.50% | 28.67% | 4.72% | -18.40% |
| Operating Income | -13.42% | -40.69% | -64.05% | 17.30% | 4.48% |
| Income Before Tax | 12.01% | -66.18% | -65.28% | 27.64% | -6.08% |
| Income Tax Expenses | -7.51% | 36.41% | 110.90% | 723.05% | 201.74% |
| Earnings from Continuing Operations | 11.43% | -62.22% | -69.92% | 11.36% | -44.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.43% | -62.22% | -69.92% | 11.36% | -44.34% |
| EBIT | -13.42% | -40.69% | -64.05% | 17.30% | 4.48% |
| EBITDA | -13.57% | -41.26% | -65.06% | 17.49% | 4.59% |
| EPS Basic | 15.53% | -42.35% | -36.47% | 29.79% | -16.77% |
| Normalized Basic EPS | 16.15% | -43.91% | -31.35% | 43.24% | 15.96% |
| EPS Diluted | 15.53% | -42.35% | -36.47% | 29.79% | -16.77% |
| Normalized Diluted EPS | 16.15% | -43.91% | -31.35% | 43.24% | 15.96% |
| Average Basic Shares Outstanding | 6.36% | 13.27% | 20.62% | 24.90% | 21.72% |
| Average Diluted Shares Outstanding | 6.36% | 13.27% | 20.62% | 24.90% | 21.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |